Profusa Withdraws S-1 for Large Offering, Plans Smaller Capital Raise
PFSA is trading near its 52-week low of $1.06 (10% above the low) on elevated volume (21× avg).
Summary
Profusa has announced its decision to withdraw the S-1 registration statement for a public offering, which was originally filed on February 13, 2026. The company stated that, after reevaluating its near-term capital needs and considering recent changes in projected 2026 revenue and the Mayo Collaboration, a $15 million offering is no longer required. This move follows previous SEC filings (S-1, S-1/A, 424B3) that detailed the initial offering and potential significant dilution. Profusa now intends to pursue a smaller, more focused offering, which is a positive development for existing shareholders as it implies less dilution than previously anticipated. The company aims to support its projected Q2 2026 Europe LumeeTM Oxygen product revenue and investment in the Mayo collaboration for U.S. market entry. Investors should monitor for details of the new, smaller offering and the progress of its commercial launches.
At the time of this announcement, PFSA was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $1.06 to $975.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.